Abstract. Dendritic cells (DCs) play a pivotal role in T cellmediated immunity and have been shown to induce strong anti-tumor immune responses. As of yet, only a limited number of objective tumor regressions have been observed in clinical studies using a DC vaccine. Suppressor of cytokine signaling-1 (SOCS1) is a key negative regulator of the JAK/STAT signal pathway and plays an essential role in suppressing systemic autoimmunity that is mediated by DCs. The aim of this study was to investigate whether SOCS1-silenced DCs can break the vaccine-induced immune tolerance stimulated by highdose DC, thereby enhancing anti-tumor activity. In the mouse melanoma model, we found that a 2x10 6 TRP2-pulsed DC vaccine was able to induce immune tolerance, while a 2x10 6 SOCS1-silenced DC/TRP2 vaccine prevented immune tolerance. Further experiments revealed that activation-induced T cell death (AICD) through the Fas/Fas-L pathway may play a crucial role in immune tolerance induced by 2x10 6 TRP2-pulsed DC. SOCS1-silencing in DCs could prevent immune tolerance by inhibiting Fas and Fas-L expression, induced by an increase in IL-12p70 and IL-6 production. In addition, in 2x10 6 SOCS1-silenced DC/TRP2 immunized mice, higher levels of IL-12p70 and IFN-γ and lower IL-17 production may inhibit tumor angiogenesis and therefore assist in breaking immune tolerance. In conclusion, high-doses of DCs can inhibit the vaccine-induced AICD of T cells and cytokine regulation in tumor angiogenesis. These results indicate that SOCS1-silenced DC vaccines may greatly enhance anti-tumor activity by breaking self-tolerance.
Introduction
Dendritic cells (DCs) are professional antigen-presenting cells (APC) with key regulatory functions in the maintenance of tolerance to self-antigens and in the activation of innate and adaptive immunity (1) . Suppressor of cytokine signaling-1 (SOCS1) serves to negatively regulate signaling of various cytokines, such as interferon (IFN)-γ, interleukin (IL)-2, IL-6, IL-7, IL-12 and IL-15, by inhibiting the Janus kinases (JAKs) in T cells and other immune cells (2, 3) . The stimulatory capacity of DCs, as well as the magnitude of adaptive immunity, are critically regulated by SOCS1 (4). SOCS1 acts as an antigen-presentation attenuator by controlling the tolerogenic state of DCs and the magnitude of antigen presentation. Inhibition of SOCS1 significantly enhances the ability of DC-based tumor vaccines to break self-tolerance and to effectively induce anti-tumor immunity (4) .
Although the results of various DC trials are exciting, the use of DCs in the clinic has achieved only limited success. The treated patients have not experienced tumor regression suggesting that the DC dose, route of administration and choice of antigen may need to be optimized (5) . In addition, the results differ greatly due to the varied doses of DCs that have been used (6) (7) (8) (9) . In order to attain sufficient anti-tumor immunity, it may be necessary to use high doses of DCs in clinical trials (10) .
Several mechanisms are involved in the induction of immune tolerance. Clonal anergy has been shown to be a major mechanism of certain immune tolerance states, such as oral tolerance and superantigen-induced tolerance (11) (12) (13) (14) . CD95(Fas)-dependent activation-induced cell death (AICD) appears to participate in maintaining peripheral tolerance by removing T cells specific for self-antigen, represented by high doses of systemic antigen in the absence of adjuvants (15) (16) (17) . CD4 + CD25 + Treg cells have also been shown to play a major role in the maintenance of peripheral tolerance (18) , and immune tolerance in vivo and in vitro can be induced by a signal from CTLA-4 (19, 20) . In addition, ICOS molecules play an essential and specific role in mucosal tolerance, and distinct co-stimulatory pathways differentially regulate peripheral tolerance. 
SOCS1 silencing can break high-dose dendritic cell immunotherapy-induced immune tolerance
There is much evidence pointing towards the involvement of DCs in the induction of tolerance (21) (22) (23) (24) (25) . The outcome of T cell stimulation by steady-state, antigen-loaded DCs can be apoptosis (25, 26) , anergy of T cells in the periphery (27) or the induction of regulatory T (Treg) cells (25, 28) , depending on the state of DC maturation. Each of these mechanisms can result in some form of T cell tolerance (29) ; however, Tregs, CTLA-4 and ICOS were not related to immune tolerance in our study (data not shown).
In addition, angiogenesis, the formation of new blood vessels from the endothelium of the existing vasculature, is fundamental for tumor growth, progression and metastasis. Inhibiting tumor angiogenesis should slow tumor growth and is a promising strategy for cancer treatment (30) . A large body of evidence indicates that cytokines, such as IFN-γ and IL-12p70, could inhibit tumor angiogenesis, while IL-17 could promote it (31) (32) (33) (34) (35) . Since SOCS1 functions as a negative regulator of signaling by various cytokines, silencing SOCS1 in bone marrow-derived DCs (BMDC) must change the production of some cytokines. The altered production of these cytokines could influence tumor growth and immune tolerance.
In this study, we found that SOCS-silencing could break the immune tolerance induced by 2x10 6 TRP2-pulsed DC vaccine. We then proceeded to investigate the mechanisms involved in this immune tolerance. We examined the role of activation-induced T cells apoptosis, and the secretion of certain cytokines (Th1, Th2 and IL-17) from spleen mononuclear cells (MNCs) of mice, which were immunized with different doses of DC/TRP2 or SOCS1-silenced DC/TRP2. Results showed that SOCS1-silencing in DCs could inhibit T cell apoptosis, enhance the secretion of IFN-γ, IL-12p70 and IL-6, and decrease IL-17 production. This study broadens the understanding of the function of SOCS1 protein and its usage in clinical trails.
Materials and methods
Cell lines and animals. B16 cell line (CRL-6475, ATCC, H-2 b ) was cultured in DMEM (Hyclone, Logan, UT) supplemented with 10% heat-inactivated FCS (Hyclone), 2 mM L-glutamine, 100 IU/ml penicillin and 100 mg/ml streptomycin.
Four to 6 week-old female C57BL/6 (H-2 b ) mice were purchased from SLAC Laboratory (Shanghai, P.R. China) and kept under controlled temperature (22-23˚C) and a 12-h light/dark cycle with free access to water and pelleted food. Care and maintenance of all animals were in accordance with the Institutional Animal Care and Use Committee (IACUS) guidelines set by Shanghai Institutes for Biological Sciences.
Peptide and siRNA. The TRP2 peptide VYDFFVWL of B16 cell line was synthesized by GL Biochem (Shanghai) Ltd. and purified by HPLC.
Mouse SCOS1 siRNA (5'-CTA CCT GAG TTC CTT CCC CTT-3') and mouse SOCS1 siRNA mutant (5'-CTA TCT AAG TTA CTA CCC CTT-3'), described previously (4), were synthesized by Shanghai Genepharma Co. Ltd.
Generation of DC from bone marrow cultures.
The protocols used in this study are as previously described (4, 22, 36) , with some minor modifications. Briefly, bone marrow cells from C57BL/6 mice were flushed from femurs and tibias. Red blood cells were removed by lysis with ammonium chloride. Bone marrow progenitors were seeded in a 24-well plate (1-2x10 6 cells/ml, 1 ml/well) in RPMI-1640 (Hyclone) supplemented with 10% heat-inactivated FCS, 20 ng/ml recombinant murine GM-CSF (PeproTech, Inc.), 50 μM 2-ME, 10 mM HEPES, 2 mM glutamine, 100 IU/ml penicillin and 100 mg/ml streptomycin. The cultures were fed every 2 days by gently aspirating 75% of the medium and adding fresh medium containing mGM-CSF. On day 6, non-adherent and loosely adherent proliferating DCs were collected and counted, then pulsed with TRP2 peptide (50 μg/ml) for 8 h. Antigen-pulsed DCs were stimulated with 200 ng/ml LPS (Sigma-Aldrich) in 1640 CM10 for 24 h. The collected DCs were washed twice with PBS, and resuspended in PBS for injection.
DC transfection with siRNA oligo. Bone marrow-derived DCs were transfected with 21 base-pair SOCS1 siRNA oligonucleotides or SOCS1 siRNA mutant using Geneporter, following the manufacturer's protocols. Briefly, 3 μl of 20 μM oligonucleotides was added to 3 μl of geneporter reagent and 94 μl of serum-free RPMI-1640 and incubated at room temperature for 30-45 min. Thereafter, 100 μl of the Geneporter oligonucleotide mixture was added to each well of DC and incubated for 4 h at 37˚C. Following incubation, 500 μl/ well of RPMI-1640 supplemented with 20% FBS was added to bone marrow DCs.
DC immunization and tumor models. Different doses of TRP2 peptide pulsed DC, SOCS1-silenced DC (DC-S1) or DC-S1 mutant in 100 μl PBS were injected into C57BL/6 mice twice weekly via footpad, followed by in vivo stimulation of LPS [30 μg in 200 μl PBS intraperitoneally (i.p.)] once daily for 3 days. One week following the second immunization, C57/BL6 mice were challenged subcutaneously (s.c.) in the left flank with B16 cells (2.5x10 5 /mouse). Tumor volumes were measured 2-3 times a week with a caliper.
In the high-dose DC immunization experiment, C57BL/6J mice were immunized with 2x10 6 TRP2 pulsed DC, DC-S1 or DC-S1 mutant twice every two weeks. One week following the second immunization, mice from the above groups and the PBS control were s.c. inoculated with 2.5x10 5 B16 cells, respectively. Tumor volume was monitored every 2-3 days.
IFN-γ enzyme-linked immunospot assay. IFN-γ secretion, in response to specific antigens at the single-cell level, was detected by an enzyme-linked immunospot (ELISPOT) assay (BD Biosciences, San Diego, CA). Ninety 6-well PVDF microplates were coated overnight with an anti-murine IFN-γ monoclonal antibody. The plates were washed 6 times with PBS and blocked with RPMI-1640 containing 10% FBS at 37˚C for 2 h. Splenocytes (5x10 5 ) were seeded into wells and incubated with 20 μg/ml TRP2 peptide for 20 h at 37˚C in 5% CO 2 . Irrelevant peptide was also used as a negative control. The cells were then washed 6 times with PBS/0.5% Tween-20. Biotinylated anti-mouse IFN-γ antibody (1 μg/ml), diluted in PBS containing 0.5% FBS was added and incubated at 25˚C for 2 h. Streptavidin-alkaline phosphatase was added and incubated at room temperature for an additional hour. Cytokine-secreting cells were detected after a 15-30-min reaction at room temperature in the dark with AEC (3-amino-9-ethylcarbazole) and the reaction was terminated with distilled water washes. The membranes were air-dried and spots per well were subjected to automated evaluation using the ImmunoSpot Imaging Analyzer system (Cellular Technology Ltd., Cleveland, OH). IFN-γ secreting cell numbers were calculated by averaging the number of spots from 3 replicate wells and expressed as the average number of spots per well ± SD.
Cytotoxicity assay by LDH release. The cytotoxic responses of T cells (mainly CD8
+ T cells) from 1x10 6 DC, 2x10 6 DC, 2x10 6 DC-S1 and 2x10 6 DC-S1 mutant immunized mice were assessed with LDH release assay (Cytotox 96 ® nonradioactive cytotoxicity assay, Promega Corp., Madison, WI, USA). The splenocytes, which were suspended in complete RPMI-1640 containing 10% FCS and 50 μmol/l 2-mercaptoethanol, were incubated with 20 μg/ml TRP2 peptide in vitro. Cytotoxic effector lymphocyte populations were harvested after 3 days of incubation. LDH-release assay was performed in a 96-well round bottom plate using B16 cells as the target cell. Cytotoxic T cells (CTL) assays were performed using lymphocyte effector:target (E:T) ratios of 20:1, 40:1, and 80:1. The percentage of specific lysis was calculated according to formula provided by the manufacturer.
Measurement of cytokine production. Spleen MNCs were prepared 7-11 days after the second DC immunization. Viable cells (2x10 6 ) were cultured in complete medium with TRP2 peptide at 20 μg/ml. Supernatants from stimulated cells were collected at 24-72 h and the levels of IFN-γ, IL-4, IL-6, IL-10, IL-12p70, TGF-ß and IL-17 were measured by ELISA (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. A standard curve was performed for each plate and used to calculate the absolute concentrations of cytokines.
Quantitative real-time PCR. CD4
+ T cells were isolated with Dynabeads mouse CD4 (L3T4) kit (Dynal Biotech, Norway) according to the manufacturer's directions. Total-RNA was extracted from spleen MNCs or CD4 + T cells with RNeasy Mini kit (Qiagen, Hilden, Germany), followed by first-strand cDNA synthesis using Sensiscript RT kit (Qiagen), according to the manufacturer's instructions. Quantitative real-time RT-PCR was performed on a PRISM 7900 sequence detection system (Applied Biosystems, UK) with primer pairs using SYBR ® green PCR master mix (Applied Biosystems). ß-actin was used as a reference for sample normalization. Relative quantification of gene expression was calculated by using a ΔCT method based on signal intensity of PCR results, according to the following formula The annexin V/propidium iodide (PI) assay was used to measure the amount of apoptosis of T cells, whereby spleen MNCs from DC or DC-S1 immunized mice (n=4) were stimulated with 20 μg/ml TRP2 peptide for 24 h. Cells (1x10 5 ) were incubated with Annexin V-FITC and PI (BD Pharmingen, San Diego, CA) at room temperature for 15 min according to the manufacturer's instructions. Within one hour, stained cells were analyzed by FACS.
For the detection of Fas expression on CD4 + and CD8 + T cells of stimulated spleen MNCs, cells were incubated with FITC-conjugated anti-mouse CD4/CD8 antibodies and PE-conjugated anti-mouse Fas/CD95 (eBiosciences) or their isotype control antibodies for 30 min at 4˚C, followed by washing and fixation with 2% paraformaldehyde. Cells were then stored at 4˚C for further FACS analysis.
Statistical analyses. All statistical analyses in this study were performed with the Student's t-test, and a probability of <95% confidence limit was considered to be significant, defined as p<0.05. Results are presented as means ± standard deviation (SD).
Results

Maturation status of BM-DC/TRP2 and SOCS1-silenced BM-DC/TRP2.
To determine the maturation status of BM-DC/TRP2 and SOCS1-silenced BM-DC/TRP2, FACS analysis was performed on cell suspensions from day 7. DCs were prepared from bone marrow precursors and harvested for use 7 days after culture in 1640 CM10 media containing mGM-CSF. After SOCS1 silencing, TRP2 peptide loading, and LPS stimulation in vitro, DCs were stained by flow cytometry to analyze surface expression of CD11c, MHC I/II molecules, co-stimulatory molecules and antigens associated with maturation. The data showed that DCs expressed high levels of the above-mentioned surface molecules, and mature SOCS1-silenced BM-DC/TRP2 express more DC markers, co-stimulatory molecules, MHC class I and class II molecules than mature DC/TRP2 (Fig. 1A) . The production of IL-4, IL-6, IL-10, IL-12p70 and TNF-α by SOCS1-silenced BM-DC/TRP2 and DC/TRP2 in culture supernatant was measured after stimulation with 200 ng/ml of LPS for 24 h. Both SOCS1-silenced BM-DC/TRP2 and DC/TRP2 secreted high levels of IL-6, IL-12p70 and TNF-α, but the levels of the three cytokines produced by DC-S1 were higher than DC (Fig. 1B) .
Silencing SOCS1 can break tolerance induced by highdosage DC inoculation. To evaluate the anti-tumor immunity of different doses of DC, C57BL/6J mice (n=10) were inoculated with 5x10 5 , 1x10 6 , 2x10 6 TRP2-pulsed BMDC. PBS was used as a control. One week after the second immunization, the mice were challenged with B16 cells. As shown in Fig. 2a , there was a significant difference in antitumor immunity among the TRP2-pulsed DC groups (p<0.05). Anti-tumor immunity was induced effectively with 5x10 5 and 1x10 6 TRP2-pulsed DCs, while 2x10 6 TRP2-pulsed DCs induced immune tolerance.
To determine the role of SOCS1-silencing in immune tolerance, anti-tumor immunity of 2x10 6 DC/TRP2, DC-S1/ TRP2 and DC-S1 mutant/TRP2 were compared in the mouse B16 model. One week after the second immunization, mice from the immunized groups and PBS control group were inoculated subcutaneously with 2.5x10 5 B16 cells. The tumor volume was monitored every 2-3 days. As shown in Fig. 2b , the tumor volume of mice inoculated with 2x10
6 DC-S1/TRP2 displayed a significant difference (p<0.01) versus 2x10 6 DC-S1 mutant /TRP2 and PBS control groups, as well as the 2x10 6 DC/TRP2 group (p<0.05). The results suggest that SOCS1-silencing could terminate the immune tolerance induced by 2x10 6 DC/TRP2. Furthermore, as shown in Fig. 2c , the tumor volume of mice immunized with different doses of DC-S1 was significantly decreased (p<0.05 for 5x10 5 and 1x10 6 ; p<0.01 for 2x10 6 ) versus different dose DC or DC-S1 mutant immunized groups.
In survival studies (Fig. 2d ), C57BL/6 mice (n=7) were immunized with 2x10 6 DC-S1, DC-S1 mutant, DC and PBS control twice, and subsequently challenged with B16 tumor cells as above. All mice challenged with PBS and 2x10 6 DC died within 32 days post-B16 cell challenge. Two mice in the 2x10 6 DC-S1 group displayed no visible tumor growth and survived past 10 weeks. The survival rate of the 2x10 6 DC-S1 group was significantly higher (p<0.05) than the 2x10 6 DC or DC-S1 mutant and PBS control groups (p<0.05).
Antigen specific T cell responses ex vivo. SOCS1 contributes to the regulation of DC stimulation of antigen-specific T cells (4) . To measure the antigen-specific cellular response induced by 2x10 6 SOCS1-silenced DCs, IFN-γ secreting frequency assay by ELISPOT and CTL activities by LDH assay were performed. As shown in Fig. 3a, IFN-γ spots (514±16 and 189±98) were detected ex vivo by ELISPOT in 5x10 5 spleen MNCs of mice (n=4) that had been immunized two times with 2x10 6 SOCS1-silenced DC/TRP2 and 2x10 6 DC/TRP2, respectively; there was a significant difference between the two groups (p<0.05). Cytotoxicity of antigenspecific T cells (CTLs, mainly CD8 + T cells) is an important marker of anti-tumor immunity. For this reason, we compared the CTLs in vitro from 1x10 6 DC, 2x10 6 DC, 2x10 6 DC-S1 and 2x10
6 DC-S1 mutant immunized mice. As shown in Fig. 3b , CTL assays showed potent cytotoxicity against B16 cells in 2x10 6 SOCS1-silenced DC/TRP2 immunized mice, but not in the 2x10 6 DC/TRP2 or 2x10 6 DC-S1 mutant group. Active cytotoxicity against B16 cells in 2x10 6 DC-S1 immunized mice was significantly different from that detected in 2x10 6 DC immunized mice (p<0.05). In addition, 1x10 6 DC was also significantly different from 2x10 6 DC immunized mice (p<0.05).
T cell apoptosis plays a crucial role in immune tolerance induced by 2x10
6 DC inoculation. To examine whether immune tolerance induced by 2x10 6 DC inoculation was related to activation-induced T cell death (AICD), apotosis measurements were performed with annexin V/PI staining. Annexin V identifies cells in the early stages of apoptosis. Cells in the late stages of apoptosis will have a damaged membrane and, therefore, stain positive for PI, as well as for annexin V. The spleen MNCs from 2x10 6 , 1x10 6 and 5x10 annexin V-FITC/PI staining (BD Pharmingen). As shown in Fig. 4a , annexin V-FITC positive cells were almost 2-fold (21.08%) greater in the 2x10 6 DC/TRP2 group than in the other groups (8.31-11.78%).
To investigate, in the 2x10 6 DC/TRP2 group, the role of Fas/FasL signaling in T cell apoptosis, we examined Fas (CD95) expression on 6 DC /TRP2 immunized mice was higher than 2x10 6 DC-S1/TRP2 and 1x10 6 DC/TRP2 immunized mice. Conversely, the relative Fas-L mRNA expression of CD4 + T cells from 1x10 6 and 2x10 6 DC-S1/TRP2 immunized mice was almost 5-fold higher than that of 2x10 6 DC-S1/T RP2 immunized mice (Fig. 4b) . Both Fas and Fas-L molecules were highly expressed on CD4 + T cells from 2x10 6 DC-S1/TRP2 immunized mice, which indicates that the expression of Fas-L in CD4 + T cells could be sufficient to induce apoptosis. Lower Fas and Fas-L expression in T cells may explain why apoptosis induction was lower in 2x10 6 DC- 
S1/TRP2 immunized mice than that in 2x10
6 DC/TRP2-immunized mice. In addition, Bcl-2 mRNA expression was not significantly different among 1x10 6 DC/TRP2, 2x10 6 DC/TRP2 and 2x10 6 DC-S1/TRP2 groups (Fig. 4c) .
IL-12p70 and IL-6 production in DC-immunized mice.
Since SOCS1 negatively regulates the signaling of various cytokines, breaking the immune tolerance by SOCS1-silenced dendritic cells must be related to altered production of certain cytokines. To determine the mechanism by which 2x10 6 SOCS1-silenced DC/TRP2 can break immune tolerance, cytokine profiles of cultured spleen MNC supernatants of immunized mice were analyzed by ELISA. IL-12 has been shown to inhibit apoptosis of CD4 + and CD8 + T cells by decreasing Fas-L expression and promoting FLIP expression (37, 38) . As shown in Fig. 5a , the level of IL-12p70 was measured by ELISA. The results showed that IL-12p70 production in the 2x10 6 DC-S1/TRP2 group was significantly higher than that of the 2x10 6 DC/TRP2 and 2x10 6 DC-S1 mutant/TRP2 groups (p<0.01). In the other two SOCS1-silenced DC groups, IL-12p70 production was also higher than the corresponding DC dose group (p<0.05). We suggest that IL-12 might act as an inhibitor of immune tolerance induced by high-dose DC. Lower Fas-L mRNA expression in CD4 + T cells from 2x10 6 DC-S1/TRP2 immunized mice (Fig. 4b) indicates an indirect role for IL-12. IL-6 also prevented activation-induced T cell death by inhibiting Fas/Fas-L expression (39) . As shown in Fig. 5b , the level of IL-6 in the 2x10 6 DC-S1/TRP2 group was significantly higher than that of the 2x10 6 DC/TRP2 and 2x10 6 DC-S1 mutant/TRP2 groups (p<0.05).
Tumor angiogenesis-related cytokines production. Immune tolerance observed in our study was based mainly on tumor volume changes. This underscores the importance of understanding and studying the factors that influence tumor growth. Some studies have already indicated that tumor growth is an angiogenesis-dependent process that requires sustained new vessel growth (31), and IFN-γ and IL-17 have been confirmed to inhibit/promote tumor angiogenesis, respectively. To evaluate the effect of SOCS1-silencing on tumor angiogenesis-related cytokine production in our studies, the secretion levels of IFN-γ and IL-17 were measured.
As shown in Fig. 6a , IFN-γ production in the 5x10 5 , 1x10 6 and 2x10 6 DC-S1 groups was significantly higher than that of the corresponding doses in DC groups (p<0.05); however, there was no significant difference among the DC-S1 groups (p>0.05). IFN-γ production in 2x10 6 DC immunized mice showed a large standard deviation (SD) (Fig. 6a) , suggesting that IFN-γ secreting T cells may be at different apoptotic stages (activation-induced cell death was detected in this study).
Substantial evidence suggests that IL-17 could promote angiogenesis and tumor growth (31, 40) . To determine whether IL-17 cytokine production was different between the high-dose DC/TRP2 group and the DC-S1/TRP2 group in the B16 model, levels of IL-17 from cultured supernatants were measured by ELISA. Significantly lower levels of IL-17 production were measured by ELISA in the 2x10 6 DC-S1-immunized mice compared to the 1x10 6 DC and 2x10 6 DCimmunized mice (p<0.05, Fig. 6b) .
IL-23 serves to expand previously differentiated TH-17 cell populations, whereas IL-6 and transforming growth factor-ß (TGF-ß) induced differentiation of TH-17 cells from naive precursors (41) . However, levels of IL-6 (Fig. 5b,  p<0 .05) and TGF-ß (data not shown) in 2x10 6 DC immunized mice were significantly lower than those in 2x10 6 DC-S1 immunized mice, so we measured IL-23 mRNA expression by quantitative real-time PCR. As shown in Fig. 6c , IL-23 mRNA expression in different doses of SOCS1-silenced DC/TRp2 groups is lower than that of corresponding doses of DC/TRP2 groups, suggesting that decreased IL-23 expression may contribute to lower IL-17 production in 2x10 6 DC-S1-immunized mice.
Discussion
The determination of a lymphocyte to affect either tolerance or immunity is regulated at many levels. Two important parameters in this decision are the maturation state of the Figure 5 . The production of IL-12p70 and IL-6, which could inhibit Fas and/or Fas-L expression, was measured by ELISA. C57BL/6 mice were immunized twice with different doses of TRP2-pulsed DC, DC-S1 and DC-S1 mutant respectively. Two weeks after second DC inoculation, the spleen MNCs from mice of three groups (n=4) were cultured with 20 μg/ml TRP2 peptide for 72 h. The levels of IL-12p70 (a) and IL-6 (b) in culture supernatant were measured by ELISA. Asterisks indicate statistically significant differences between two groups ( * p<0.05, ** p<0.01).
APCs and the amount of antigen detected by the immune system (42) . The maturation state of DCs is considered to be a key determinant for the outcome of T cell activation (1, 22) . For example, immature DCs can anergize autoreative T cells in the periphery or lead to the induction of regulatory T cells (24) . Semi-mature DCs have also been shown to induce tolerance (29 (22) . In our study, prepared bone marrow-derived DC/TRP2 or SOCS1-silenced DC/TRP2 expressed high levels of MHC and co-stimulatory molecules and secreted high levels of IL-12, TNF-α and IL-6. Moreover, these DCs induced effective anti-tumor immunity in immunized C57BL/6J mice. As a result, we concluded that prepared DCs were fully mature.
SOCS1 plays a crucial role in regulating the extent of DC antigen presentation, and the modulation of a DC regulatory mechanism has been an effective way to control the magnitude and duration of adaptive immunity (4, 43) . In our study, SOCS1-silenced DCs displayed higher levels of CD11c, MHC and co-stimulatory molecules. We therefore conclude that immunization in mice can lead to changes in cytokine production, the extent of T cell activation and the modulation of these mechanisms.
Activation-induced cell death (AICD) is a process in which T cell activation, by way of the T cell receptor, results in apoptosis (44) . AICD plays a key role in tolerance induction and lymphocyte homeostasis. The results of annexin V/PI staining showed that the proportion of cells at early stages of apoptosis in the 2x10 6 TRP2-pulsed DC group was 2-fold greater in contrast to other groups, which suggests that apoptosis is an important factor for immune tolerance. The Fas/Fas ligand pathway is the predominant mechanism for AICD in peripheral T cells (44) . Flow cytometry analysis showed Fas expression was higher in both CD4 + and CD8 + T cells from the 2x10 6 TRP2-pulsed DC group than the other groups. It was suggested that both CD4 + and CD8 + T cells underwent apoptosis. It has been shown that in order to aquire an optimal anti-tumor immune response, the concomitant activation of both the CD4 + and CD8 + T cell arm of the immune response is required (45) . A potent CD8 + CTL response is the key to protective immune responses against tumors. Accumulating evidence strongly suggests that the CD4 + T cell arm of the immune response also plays a critical role in mediating anti-tumor immunity (46, 47) . This suggests that apoptosis of CD4 + and CD8 + T cells should lead to immune tolerance.
Why are 2x10 6 SOCS1-silenced DC/TRP2 inoculated cells resistant to apoptosis? According to our data, Fas expression of CD4 + and CD8 + T cells in the 2x10 6 SOCS1-silenced DC/TRP2 group was similar to lower dose DC groups. Since IFN-γ has been previously shown to up-regulate Fas expression in vitro and in vivo (48, 49) , we proceeded to measure IFN-γ production. Our results showed that the production of IFN-γ was significantly higher in the various doses of DC-S1/TRP2-immunized mice than DC/TRP2 and DC-S1 mutant/TRP2-immunized mice. Nevertheless, Fas expression was up-regulated nearly 2-fold in the 2x10 6 DC-immunized group when compared to the other groups. It is assumed that certain factors, which existed in the 2x10 6 SOCS1-silenced DC-immunized mice, inhibited T cell apoptosis by decreasing Fas expression. Figure 6 . The production of IFN-γ and IL-17, influencing angiogenesis, was measured by ELISA. C57BL/6 mice were immunized twice with different doses of TRP2-pulsed DC, DC-S1 and DC-S1 mutant respectively. Two weeks after second DC inoculation, the spleen MNCs from mice of three groups (n=4) were cultured with 20 μg/ml TRP2 peptide for 72 h. The levels of IFN-γ (a) and IL-17 (b) in culture supernatants were measured by ELISA. (c) IL-23 mRNA expression in spleen MNCs was measured by real-time PCR. Spleen MNCs were cultured in vitro with 20 μg/ml TRP2 peptide for 24 h. Quantitative real-time PCR was performed using SYBR green on an ABI PRISM 7900 sequence detection system. Asterisks indicate statistically significant differences between a given group and the other groups ( * p<0.05).
Substantial evidence has led to the belief that IL-12 and IL-6 can inhibit Fas and/or Fas-L expression in T cells in AICD. IL-12 has been shown to inhibit apoptosis of CD4 + and CD8 + T cells and can prevent activation-induced or Fasmediated apoptosis of human CD4 T cells (37) . In the mouse, neutralization of endogenous IL-12 promoted Fas-mediated apoptosis of CD4 T cells in vivo (50) and co-stimulation with IL-12 significantly prevented anti-CD3-induced apoptosis of CD8 T cells (38) . It was also shown that IL-12 decreased the number of Fas ligand-positive CD8 T cells and inhibited the activation of caspase-8 and -3. In addition, IL-12 upregulated cellular FLIPs, but not Bcl-2 family proteins or the cellular inhibitors of apoptosis proteins (38) . In our study, the level of IL-12 in the 2x10 6 SOCS1-silenced DCimmunized group was significantly higher than that of the 2x10 6 DC/TRP2 and 2x10 6 DC-S1 mutant/TRP2-immunized groups (p<0.01). Therefore, up-regulated IL-12 likely led to reduced apoptosis in the 2x10 6 SOCS1-silenced DC/TRP2 immunized group. Decreased Fas-L mRNA expression in this group, along with no significant difference in Bcl-2 mRNA expression among the 1x10 6 DC/TRP2, 2x10 6 DC/TRP2 and 2x10 6 DC-S1/TRP2 groups, are a further indication that IL-12 up-regulation contributes to reduced apoptosis.
Previous studies have shown that IL-6 reduced the level of activation-induced cell death and the expression of Fas/Fas-L, yet it failed to inhibit IL-2 production (39). For this reason, IL-6 may be another important factor that prevented apoptosis in the 2x10 6 SOCS1-silenced DC-immunized group, since IL-6 production was significantly higher than in the 2x10 6 DC/TRP2-immunized group.
The secretion of IFN-γ by CD4 + T cells has been shown to slow early tumor growth by inhibiting tumor angiogenesis (32, 33) . IL-12 was also shown to exert anti-tumor immunity by inhibiting angiogenesis (34, 35, 51) . This is further supported by studies showing that endogenous IL-12 could trigger an anti-angiogenic response in B16 melanoma cells (52) . In addition, studies have shown that IL-17, which is secreted mainly by Th-17 cells, could promote angiogenesis in a variety of models and induce matrix metalloproteinases (MMPs), both of which can potentiate tumor growth (31, 40, 53) . The level of IL-17 production in 2x10 6 SOCS1-silenced DC/TRP2-immunized mice was reduced by half in the 2x10 6 DC/TRP2 and 2x10 6 DC-S1 mutant/TRP2-immunized mice. It has been shown that IFN-γ and IL-4 can down-regulate IL-17 production (54,55) and both negatively regulate T helper cell production of IL-17 during the effector phase (54) . Because of lower IL-6 and TGF-ß production and higher IL-23 mRNA expression in 2x10 6 DC/TRP2-immunized mice, we deduced that higher levels of IL-4 (data not shown) and IFN-γ in 2x10 6 DC-S1/TRP2-immunized mice suppressed IL-17 production by inhibiting IL-23 production. Therefore, in the 2x10 6 SOCS1-silenced DC-immunized mice, higher levels of IFN-γ and IL-12p70, as well as lower IL-17 levels, could possibly have contributed to the enhanced anti-tumor immunity by inhibiting tumor growth. Inhibition of tumor growth, therefore, may play a partial role in breaking the immune tolerance.
As described above, activation-induced cell death plays a crucial role in immune tolerance induced by 2x10 6 DC/TRP2, while SOCS1-silencing could break it through elevated levels of IL-12p70 and IL-6. In addition, higher IFN-γ and IL-12p70, as well as lower IL-17 production, which inhibit tumor angiogenesis, could also serve as an important factor for breaking the immune tolerance.
